Abiomed issued a recall for 10,153 Automated Impella Controllers on October 1, 2025. The devices face potential cybersecurity vulnerabilities related to their operating system. Healthcare providers and patients should stop using these devices immediately.
Potential cybersecurity vulnerabilities related to the operating system in the Automated Impella Controller (AIC).
Patients and healthcare providers should stop using this device immediately. Follow the recall instructions provided by the manufacturer. Contact Abiomed, Inc. or your healthcare provider for instructions. Notification method: Letter
Get instant alerts for Health & Personal Care recalls
Be the first to know. Free instant alerts to your inbox.
The recall involves multiple models of the Automated Impella Controller, including product codes 0042-0000-AU, 0042-0000-CA, 0042-0000-EU, and others. The devices were distributed nationwide and internationally, including in Europe and Asia.
The recall stems from potential cybersecurity vulnerabilities that could compromise the functionality of the Automated Impella Controller. This risk is classified as Class I, indicating a high hazard level.
As of the report date, no injuries or incidents related to this issue have been reported. The company has taken this precautionary measure to ensure patient safety.
Patients and healthcare providers should stop using the device immediately. Contact Abiomed, Inc. or your healthcare provider for further instructions and details on the recall.
For additional information, contact Abiomed at 1-800-422-8666 or visit their website at https://www.abiomed.com.
Get instant alerts for recalls that affect you. Free forever.
Taro Pharmaceuticals announced a market withdrawal of Diclofenac Sodium, Topical Gel, 3% on January 27, 2026. The withdrawal stems from out of specification viscosity results. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,057 bags of Acyclovir Sodium Injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers should cease use immediately and contact the manufacturer for guidance.
Fresenius Kabi Compounding recalled its vancomycin HCl injection on February 5, 2026, due to a lack of assurance of sterility. This Class II recall affects all lots distributed nationwide. Healthcare providers and consumers must stop using the product immediately.
Fresenius Kabi Compounding recalled 1,578 bags of vancomycin HCl injection on February 5, 2026. The company cited a lack of assurance of sterility as the reason for the recall. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,410 bags of ketamine HCl injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers and consumers must stop using this product immediately.
Fresenius Kabi Compounding recalled 10,548 bags of thiamine HCl injection on February 5, 2026. The recall follows a lack of assurance of sterility, posing a high health risk. Affected products include several lots expiring between February and May 2026.
Pro Numb Tattoo Numbing Spray was recalled due to cGMP deviations. The recall affects products distributed nationwide in the USA. Consumers should stop using the spray immediately and contact Pro Numb Tattoo Numbing Spray LLC for guidance.
Pro Numb Tattoo Numbing Spray was recalled on February 2, 2026 due to cGMP deviations. The product, containing 4% lidocaine, is distributed by Pro Numb Tattoo Numbing Spray LLC. Consumers should stop using it immediately and contact the company for further guidance.